We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)

MP Biomedicals (Eschwege, Germany) is exhibiting its wide product portfolio of POC, screening and confirmatory tests, backed by a range of testing methods that aid in the diagnosis, detection, and recovery from diseases, at MEDICA 2022.

At this year’s edition of MEDICA, MP Biomedicals is exhibiting the AutoBlot System 36, an intelligent Western Blot processor that enables automated washing and incubation of up to 36 assay strips per run at a pre-selected temperature. The AutoBlot System 36 helps to satisfy Immunoblot needs by minimizing human error, increasing productivity and delivering accurate and consistent results. MP Biomedicals is also showcasing its innovative diagnostic tests such as the Rapid SARS-CoV-2 Antigen Test Card, an IVD test for private use to detect SARS-CoV-2 antigens from anterior nasal swabs, alongside the Rapid 2019-nCoV IgG/IgM Combo Test Card, which is an immunochromatography based one-step in vitro test designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV,SARS-CoV-2) in human serum, plasma, or whole blood.

MP Biomedicals is also highlighting its POC testing and screening solutions for the qualitative assessment of drugs and their metabolites in human urine and saliva. Visitors to the MP Biomedicals booth at MEDICA 2022 can gain insights into the MP Diagnostics HIV BLOT 2.2 qualitative enzyme immunoassay for the in vitro detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. HIV BLOT 2.2 is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures such as the Enzyme-Linked Immunosorbent Assay (ELISA). Also on display at the event is the MP Diagnostics MULTISURE HIV 1/2 Confirmatory Test for use as a rapid confirmatory test to detect and differentiate antibodies specific to HIV-1 gp120, HIV-1 gp41, HIV-1 p24 and HIV-2 gp36, HIV-2 gp105 antigens in human serum or plasma.

Related Links:
MP Biomedicals

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more